| Patent application number | Description | Published |
|---|
| 20080200838 | WEARABLE, PROGRAMMABLE AUTOMATED BLOOD TESTING SYSTEM - The present invention is a programmable, automated device for measurement and analysis of blood analytes and blood parameters. The device components are preferably combined in a single housing and either programmed to initiate automatic, periodic blood sampling or initiate automatic blood sampling via operator input or in response to a predefined event or in response to a signal from another instrument. The device operates automatically to draw blood samples and analyze the drawn blood samples to obtain the desired blood readings. | 08-21-2008 |
| 20080275324 | Fluid Access Interface - The present invention relates generally to systems, apparatuses, and methods for obtaining a fluid sample from a patient. In particular, the present invention relates to a various types of fluid access interfaces for enabling contact between a patient blood sample and blood parameter sensors for the measurement of physiological parameters and blood constituents. | 11-06-2008 |
| 20090156922 | BLOOD MONITORING SYSTEM - The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter. | 06-18-2009 |
| 20120108936 | FLUID ACCESS INTERFACE - The present invention relates generally to systems, apparatuses, and methods for obtaining a fluid sample from a patient. In particular, the present invention relates to a various types of fluid access interfaces for enabling contact between a patient blood sample and blood parameter sensors for the measurement of physiological parameters and blood constituents. | 05-03-2012 |
| Patent application number | Description | Published |
|---|
| 20090123826 | METHOD OF MAKING A THIN LAYER ELECTROCHEMICAL CELL WITH SELF-FORMED SEPARATOR - A method of forming an electrochemical cell is disclosed. The method comprises contacting a negative pole layer and a positive pole layer one with the other or with an optional layer interposed therebetween. The pole layers and the optional layer therebetween are selected so as to self-form an interfacial separator layer between the pole layers upon such contacting. | 05-14-2009 |
| 20100168233 | TERBINAFINE FORMULATION - The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present. | 07-01-2010 |
| 20100222734 | Double-sided patch - The present invention provides a double-sided patch comprising a first side and a second side, wherein each of the first side and the second side of the double-sided patch is configured as a treatment patch. Furthermore, the present invention provides a double-sided patch, wherein each side of the double-sided patch shares at least one common patch component with the other side of the double-sided patch. | 09-02-2010 |
| 20100228180 | Power Source Electrode Treatment Device - The present invention provides a powered treatment device comprising at least one power source for supplying electrical energy to the device, and wherein at least one component of the power source is also configured as a power source treatment device electrode to facilitate electrical contact with a body region. In an embodiment wherein one component of the power source is configured as a power source treatment device electrode, the powered treatment device may further comprise at least one non-power source device electrode of opposite polarity from the power source treatment device electrode, wherein the at least one non-power source device electrode is electrically coupled to the at least one power source to facilitate electrical contact with a body area. | 09-09-2010 |
| Patent application number | Description | Published |
|---|
| 20080261824 | Rationale, methods, and assays for identifying novel taste cell genes and salty taste receptor targets and assays using these identified genes or gene products - This invention relates to novel rationale and methods for identifying taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salt, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Further, the invention provides specific methods of purifying, enriching, isolating or marking desired taste cell subtypes or lineages such as sweet, umami, bitter, salty, sour, fat or stem cells et al. e.g., by use of FACS, magnetic beads or other selection methods that purify, enrich, mark, or eliminate such as by use of labeled cytotoxins, cells that express or do not express one or more taste specific genes. | 10-23-2008 |
| 20090117563 | Identification of TRPML3 (MCOLN3) as a Salty Taste Receptor and Use in Assays for Identifying Taste (Salty) Modulators and/or Therapeutics that Modulate Sodium Transport, Absorption or Excretion and/or Aldosterone and/or Vasopressin Production or Release - This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The invention also relates to the discovery that the TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The invention also relates to transgenic animals that have been engineered to express or knock out TRPML3 expression and assays using TRPML3 expressing animals, cells and isolated ion channel polypeptides for identifying compounds that modulate TRPML3-associated functions including salty taste, sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. | 05-07-2009 |
| 20090208946 | Rationale, Methods, and Assays for Identifying Human and Non-Human Primate Taste Specific Genes and Use Thereof in Taste Modulator and Therapeutic Screening Assays - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 08-20-2009 |
| 20090210953 | Identification of TRPML3 (MCOLN3) as a salty taste receptor and use in assays for identifying taste (salty) modulators and/or therapeutics that modulate sodium transport, absorption or excretion and/or aldosterone, and/or vasopressin production or release - The present invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals and based thereon high-throughput mammalian and medium-throughput oocyte-based electrophysiological assays for identifying human TRPML3 modulators, preferably TRPML3 enhancers. Compounds that modulate TRPML3 function in the assay are expected to affect salty taste in humans. The inventive electrophysiological assays, such as the two-electrode voltage-clamp technique, facilitate the identification of compounds which specifically modulate human TRPML3. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit TRPML3 function. Compounds that enhance or block TRPML3 channel activity should thereby modulate salty taste. In addition, these compounds may be used to regulate sodium excretion, urinary output and other biological functions relating to sodium levels and TRPML3 related functions. | 08-20-2009 |
| 20100291125 | ETA-1 GENE AND METHODS FOR USE - The present application relates to osteopontin (Eta-1) polypeptides, nucleic acids that encode Eta-1, antibodies that specifically bind to Eta-1, and methods for enhancing an immune response in an animal. | 11-18-2010 |
| 20110281753 | RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 11-17-2011 |
